Leishmaniasis: prevention, parasite detection and treatment
Language English Country United Arab Emirates Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
22360481
DOI
10.2174/092986712799828300
PII: CMC-EPUB-20120222-004
Knihovny.cz E-resources
- MeSH
- Antiprotozoal Agents therapeutic use MeSH
- Vaccines, DNA immunology therapeutic use MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Skin Tests MeSH
- Leishmania immunology pathogenicity MeSH
- Leishmaniasis * diagnosis drug therapy prevention & control MeSH
- Humans MeSH
- Microscopy MeSH
- DNA, Protozoan analysis MeSH
- Protozoan Vaccines * immunology therapeutic use MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antiprotozoal Agents MeSH
- Vaccines, DNA MeSH
- DNA, Protozoan MeSH
- Protozoan Vaccines * MeSH
Leishmaniasis remains a public health problem worldwide, affecting approximately 12 million people in 88 countries; 50 000 die of it each year. The disease is caused by Leishmania, obligate intracellular vector-borne parasites. In spite of its huge health impact on the populations in vast areas, leishmaniasis is one of the most neglected diseases. No safe and effective vaccine currently exists against any form of human leishmaniasis. The spectrum and efficacy of available antileishmanial drugs are also limited. First part of this review discusses the approaches used for the vaccination against leishmaniasis that are based on the pathogen and includes virulent or attenuated parasites, parasites of related nonpathogenic species, whole killed parasites, parasites' subunits, DNA vaccines, and vaccines based on the saliva or saliva components of transmitting phlebotomine vector. Second part describes parasite detection and quantification using microscopy assays, cell cultures, immunodetection, and DNA-based methods, and shows a progress in the development and application of these techniques. In the third part, first-line and alternative drugs used to treat leishmaniasis are characterized, and pre-clinical research of a range of natural and synthetic compounds studied for the leishmanicidal activity is described. The review also suggests that the application of novel strategies based on advances in genetics, genomics, advanced delivery systems, and high throughput screenings for leishmanicidal compounds would lead to improvement of prevention and treatment of this disease.
References provided by Crossref.org
Gene-specific sex effects on eosinophil infiltration in leishmaniasis
Mapping the genes for susceptibility and response to Leishmania tropica in mouse